1. Description of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome
- Author
-
Kateri Levesque, Nathalie Morel, Alice Maltret, Gabriel Baron, Agathe Masseau, Pauline Orquevaux, Jean-Charles Piette, Francois Barriere, Jérome Le Bidois, Laurent Fermont, Olivier Fain, Arnaud Theulin, Francois Sassolas, Philippe Pezard, Zahir Amoura, Gaëlle Guettrot-Imbert, Delphine Le Mercier, Sophie Georgin-Lavialle, Christophe Deligny, Eric Hachulla, Luc Mouthon, Philippe Ravaud, Elisabeth Villain, Damien Bonnet, Nathalie Costedoat-Chalumeau, Holy Bezanahary, Boris Bienvenu, Gilles Blaison, Philippe Blanche, Bernard Bonnotte, Pascal Cathebras, Christine Christides, Fleur Cohen, Laurence Cohen, Edouard Devaud, Elisabeth Diot, Pierre Duhaut, Yves Dulac, Bertrand Godeau, Véronique Gournay, Céline Gronier, Loïc Guillevin, Mohamed Hamidou, Julien Haroche, Gilles Hayem, François Heitz, Richard Isnard, Moez Jallouli, Anne-Sophie Korganow, Claire Le Jeunne, François Lhote, Hugues Lucron, Jean-René Lusson, Suzel Magnier, Jacques Ninet, Nicolas Pangaud, Thomas Papo, Jean-Luc Pellegrin, Jean Loup Pennaforte, Jacques Pouchot, Françoise Sarrot-Reynauld, Nicolas Schleinitz, Pascal Seve, Bertrand Stos, Denis Vital-Durand, and Bertrand Wechsler
- Subjects
Pacemaker, Artificial ,medicine.medical_specialty ,Pediatrics ,Fetus ,Pregnancy ,Multivariate analysis ,Heart block ,business.industry ,Immunology ,Retrospective cohort study ,Dilated cardiomyopathy ,medicine.disease ,Prosthesis Implantation ,Heart Block ,Treatment Outcome ,In utero ,Internal medicine ,medicine ,Cardiology ,Humans ,Lupus Erythematosus, Systemic ,Immunology and Allergy ,Gestation ,business - Abstract
Cardiac neonatal lupus syndrome is due to anti-SSA or SSB antibodies and mainly includes congenital heart block (CHB) and dilated cardiomyopathy (DCM). Its optimal management is still debated. We report a large series of autoimmune high degree CHB.Inclusion criteria in this retrospective study were fetuses or neonates with high-degree CHB associated with maternal anti-SSA/SSB antibodies.214 CHB were included: 202 detected in utero at a median term of 23 weeks' gestation (WG) [range 16 to 39 WG] and 12 neonatal cases diagnosed at a median age of 0 days [range birth to 8 days]. The 214 cases of CHB included 202 (94.4%) third-degree CHB, 8 (3.7%) second-degree CHB, and 4 (1.9%) intermittent CHB. In multivariate analysis, the factors associated with feto-neonatal deaths (15.7%) were hydrops (p0.001; hazard ratio [HR] 12.4 [95% confidence interval (95%CI) 4.7-32.7]) and prematurity (p=0.002; HR 17.1 [95%CI 2.8-103.1]). During a median follow-up of 7 years [birth to 36 years], 148 of 187 children born alive (79.1%) had a pacemaker, 35 (18.8%, one missing data) had DCM, and 22 (11.8%) died. In multivariate analysis, factors associated with child death were in utero DCM (p=0.0157; HR 6.37 [95%CI: 1.25-32.44]), postnatal DCM (p0.0001; HR 227.58[95%CI: 24.33-2128.46]) and pacemaker implantation (p=0.0035; HR 0.11[95%CI: 0.02-0.51]). The use of fluorinated steroids was neither associated with survival nor with regression of 2nd degree CHB.In this second largest series of CHB, we confirm some of the previous results. We were unable to find data supporting the routine use of in utero fluorinated steroids.
- Published
- 2015